Safety and efficacy of levodopa-carbidopa intestinal gel: results from an open-label extension study in Japanese, Korean and Taiwanese patients with advanced Parkinson’s disease

OBJECTIVES: Levodopa-carbidopa intestinal gel (LCIG) was developed to reduce motor complications in Parkinson’s disease (PD) caused by pulsatile levodopa plasma concentrations following oral levodopa administration. Dyskinesia and ‘wearing off’ symptoms can vary between Asian and Caucasian patients...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Ther Adv Neurol Disord
Hauptverfasser: Murata, Miho, Mihara, Masahito, Hasegawa, Kazuko, Jeon, Beomseok, Tsai, Chon-Haw, Nishikawa, Noriko, Oeda, Tomoko, Yokoyama, Masayuki, Robieson, Weining Z., Chatamra, Krai, Facheris, Maurizio F., Benesh, Janet
Format: Artigo
Sprache:Inglês
Veröffentlicht: SAGE Publications 2018
Schlagworte:
Original Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5833238/
https://ncbi.nlm.nih.gov/pubmed/29511383
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756286418759315
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge